December 6, 2023 11:22 AM EST

Ten63’s deal with Boehringer; Coya sets up agreement with Dr. Reddy’s; ReNAgade’s layoffs

Ryan Cross

Senior Science Correspondent

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Ten63 Therapeutics’ drug discovery deal with Boehringer Ingelheim: The Durham, NC-based startup, which is using generative AI to develop small molecule medicines, said the agreement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ten63’s deal with Boehringer; Coya sets up agreement with Dr. Reddy’s; ReNAgade’s layoffs

Ryan Cross

Senior Science Correspondent

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ten63’s deal with Boehringer; Coya sets up agree­ment with Dr. Red­dy’s; Re­NA­gade’s lay­offs

Senior Science Correspondent

Deputy Editor

Senior Reporter

Sign up to read this article for free.

Ten63’s deal with Boehringer; Coya sets up agreement with Dr. Reddy’s; ReNAgade’s layoffs